SGLT2 Inhibitors Treatment Market Trends

Growth Drivers

• Preceding advances in drug development: The vigorously expanding drug developments are reshaping the foundation of the market. Players are penetrating into the emerging economies to unlock the complete revenue potential in this field. For instance, in March 2025, Glenmark Pharmaceuticals launched Empagliflozin in India under the brand name Glempa (10/25 mg) that includes fixed-dose combinations Glempa-L (Empagliflozin + Linagliptin) and Glempa-M (Empagliflozin + Metformin). The firm further highlighted the combination's aims to improve glycemic control in adults with type 2 diabetes mellitus, hence a positive market opportunity.

• Growing awareness of early diagnosis: The market is deliberately reaping advantages from the increasing awareness of early diagnosis. Both the public and private entities are readily investing in early screening programs to diminish complications in the long run. For instance, in April 2021, the World Health Organization (WHO) declared the launch of the Global Diabetes Compact, which is an initiative that aims at diabetes prevention and care, especially in low- and middle-income countries, hence suitable for standard market growth.

• Mutually beneficial collaborations: The leading pioneers involved in the market are readily expanding their product portfolios through exclusive drug developments and strategic partnerships. In this regard, Boehringer Ingelheim and Eli Lilly and Company in September 2023 jointly announced that the U.S. FDA approved their Jardiance (empagliflozin) 10 mg tablets for treating adults with chronic kidney disease. They further highlighted that this is the first-ever SGLT2 inhibitor to demonstrate a significant reduction in both first and recurrent hospitalizations in CKD patients, thus benefiting the overall market.

Global Diabetes Prevalence by Region (2024)

Source:  International Diabetes Federation (IDF) Diabetes Atlas 2024

Revenue Opportunities for SGLT2 Inhibitors Manufacturers

Source: Company Official Press Releases

Challenges

• Exacerbated therapeutic costs: The presence of inadequate reimbursements in developing economies and expensive drug costs remains a constant hurdle in the market. Besides, these drugs are generally excluded from national formularies, making it challenging for patients from price-sensitive regions to leverage them. Therefore, the existence of pricing restraint without any coverage of the market expansion remains extremely limited, thereby causing a major obstacle.

• Safety as a major concern: Despite the rapidly expanding demand, the market still faces risks in terms of safety concerns and regulatory warnings. This can be evidenced by the fact that these inhibitors are often and very rarely associated with mild effects such as diabetic ketoacidosis, urinary tract infections, and genital infections.  Therefore, the existence of these concerns has led to a negative impact on prescriber confidence, ultimately slowing down uptake, especially in primary care settings.